Stroke: Frequency and prediction factors of haemorrhage in patients with unidentified embolism stroke
Last Update: 2020-06-16
Search more information of high quality chemicals, good prices and reliable suppliers, visit
For patients with embolis stroke of unknown origin, the risk, location and prediction factors of hemorrhage during anti-embolism treatment are not yet clearIn a recent study published in Stroke, an authoritative journal for cardiovascular disease, researchers conducted an exploratory analysis of haemorrhage as defined by the international standard for thrombosis and hemostatic in 7,213 unidentified cases of embolism in the international NAVIGATE (global trial of the new method of devanssaban inhibitor Xa), a randomized trial comparing the efficacy of 15 mg of levath saban and aspirin of 100 mgDuring the 11-month median follow-up, subjects experienced 85 hemorrhageThe most common site was the gastrointestinal tract (38%), followed by intracranial (29%)Treatment for delavataban (risk ratio of 2.7 (95% CI 1.7-4.3), East Asian countries (HR 2.5 (95% CI 1.6-3.9), sysage pressure of 160mmHg (HR 2.2) The reduction of the rate of renal glomerular filtration (1.2 per 10mL/min/1.73m2, and 1.0-1.3) of 95% CI were independently associated with haemorrhageFive (6%) people diedOf the 15 cases of cerebral hemorrhage, 2 (13%) diedThere is no evidence that Delavsaban enters an early high-risk period after treatmentThe annualized rate of cerebral hemorrhage (0.67%) for participants in East Asian countries was six times higher in all other regions (0.11%; The distribution of the bleeding sites of delavsaban and aspirin is similarIn international randomized trials of patients with unspecified embolism, the independent predictors of haemorrhage were delavsabane, East Asian countries, elevated systolic pressure, and impaired kidney functionEast Asia is closely associated with the risk of cerebral hemorrhageThe estimated rate of glomerular filtration should be considered as a factor to distinguish the risk of bleeding
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to firstname.lastname@example.org
. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.